Evaluating Melanoma Risk in Adult Mastocytosis: Potential Impact of Detection Bias – A Registry-based Study (Sweden)
DOI:
https://doi.org/10.2340/actadv.v105.43052Keywords:
basal cell carcinoma, Comorbidity, malignant melanoma, mastocytosis, melanoma in situ, SwedenAbstract
There is some evidence that mastocytosis patients are at increased risk of skin cancer. This study aimed to assess the risk of malignant melanoma (MM), melanoma in situ (Mis), and basal cell carcinoma (BCC). A dataset was generated by individual-level record linkages between Swedish population registers including the National Patient Register (NPR), the Swedish Cancer Register (SCR), and the Population Register (PR). Adult patients with a mastocytosis diagnosis between 2001 and 2018 were identified in the SCR and NPR. For each case, 5 mastocytosis-free comparators matched on age, sex, and county of residence were randomly chosen from the PR. Records of skin cancer were identified in the SCR and NPR. In total, the study encompassed 2,040 mastocytosis patients of whom 63 had a record of MM/Mis and 168 a record of BCC. Compared with comparators, the risk of MM/Mis was more than twofold higher (OR 2.39, 95% CI 1.8–3.2). Risk estimates for BCC were also elevated (OR 1.77, 95% CI 1.49–2.14). When assessing the timing of skin cancers, a substantial portion were diagnosed near index date. Taken together, in the present study these findings of increased risk of MM/Mis and BCC in mastocytosis patients may reflect an influence of detection bias.
Downloads
References
Dahlin JS, Maurer M, Metcalfe DD, Pejler G, Sagi-Eisenberg R, Nilsson G. The ingenious mast cell: contemporary insights into mast cell behavior and function. Allergy 2022; 77: 83–99. DOI: https://doi.org/10.1111/all.14881
Maurer M, Köberle M, Metz M, Biedermann T. Mast cells: promoters of health and modulators of disease. J Allergy Clin Immunol 2019; 144: S1–3. DOI: https://doi.org/10.1016/j.jaci.2019.01.048
Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere 2021; 5: e646. DOI: https://doi.org/10.1097/HS9.0000000000000646
Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2016; 137: 35–45. DOI: https://doi.org/10.1016/j.jaci.2015.08.034
Aberer E, Sperr WR, Bretterklieber A, Avian A, Hadzijusufovic E, Kluin-Nelemans HC, et al. Clinical impact of skin lesions in mastocytosis: a multicenter study of the European Competence Network on Mastocytosis. J Invest Dermatol 2021; 141: 1719–1727. DOI: https://doi.org/10.1016/j.jid.2020.12.030
Bergström A, Hägglund H, Berglund A, Nilsson G, Lambe M. Epidemiology of mastocytosis: a population-based study (Sweden). Acta Oncol 2024; 63: 44–50. DOI: https://doi.org/10.2340/1651-226X.2024.31406
Gülen T, Akin C. Anaphylaxis and mast cell disorders. Immunol Allergy Clin North Am 2022; 42: 45–63. DOI: https://doi.org/10.1016/j.iac.2021.09.007
Donker ML, Bakker NA, Jaspers WJM, Verhage AH. Two patients with osteoporosis: initial presentation of systemic mastocytosis. J Bone Miner Metab 2008; 26: 199–202. DOI: https://doi.org/10.1007/s00774-007-0800-x
Greene LW, Asadipooya K, Corradi PF, Akin C. Endocrine manifestations of systemic mastocytosis in bone. Rev Endocr Metab Disord 2016; 17: 419–431. DOI: https://doi.org/10.1007/s11154-016-9362-3
Broesby-Olsen S, Farkas DK, Vestergaard H, Hermann AP, Møller MB, Mortz CG, et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study. Am J Hematol 2016; 91: 1069–1075. DOI: https://doi.org/10.1002/ajh.24490
Kibsgaard L, Deleuran M, Flohr C, Langan S, Braae Olesen A, Vestergaard C. How “benign” is cutaneous mastocytosis? A Danish registry-based matched cohort study. Int J Womens Dermatol 2020; 6: 294–300. DOI: https://doi.org/10.1016/j.ijwd.2020.05.013
Todd P, Garioch J, Seywright M, Rademaker M, Thomson J. Malignant melanoma and systemic mastocytosis – a possible association? Clin Exp Dermatol 1991; 16: 455–457. DOI: https://doi.org/10.1111/j.1365-2230.1991.tb01235.x
Kowalzic L, Eickenscheidt L, Seidel C, Kribus S, Ziegler H, Komar M. Telangiectasia macularis eruptiva perstans, a form of cutaneous mastocytosis, associated with malignant melanoma. J Dtsch Dermatol Ges 2009; 7: 360–362. DOI: https://doi.org/10.1111/j.1610-0387.2008.06941.x
Hägglund H, Sander B, Gülen T, Lindelöf B, Nilsson G. Increased risk of malignant melanoma in patients with systemic mastocytosis? Acta Derm Venereol 2014; 94: 583–584. DOI: https://doi.org/10.2340/00015555-1788
Donati P, Paolino G, Donati M, Panetta C. Cutaneous mastocytosis combined with eruptive melanocytic nevi and melanoma: coincidence or a linkage in the pathogenesis? J Dermatol Case Rep 2014; 8: 70–74. DOI: https://doi.org/10.3315/jdcr.2014.1179
Ruini C, Hartmann D, Flaig MJ, von Braunmühl T, Berking C. [Aggressive malignant melanoma in a patient with urticaria pigmentosa]. Hautarzt Z Dermatol Venerol Verwandte Geb 2018; 69: 45–48. DOI: https://doi.org/10.1007/s00105-018-4220-8
Capo A, Goteri G, Mozzicafreddo G, Serresi S, Giacchetti A. Melanoma and mastocytosis: is really only a coincidence? Clin Exp Dermatol 2019; 44: 76–77. DOI: https://doi.org/10.1111/ced.13717
Akdogan N, Elcin G, Gokoz O. The co-existence of cutaneous melanoma and urticaria pigmentosa in a patient with Becker’s nevus. J Cosmet Dermatol 2020; 19: 1268–1270. DOI: https://doi.org/10.1111/jocd.13243
Rydberg A, Lehman J, Markovic S, Anderson K. Mastocytosis and melanoma: a case series. Int J Dermatol 2022; 61: 603–606. DOI: https://doi.org/10.1111/ijd.15791
Svenska melanomregistret (SweMR) – kvalitetsregisterrapport, 1990–2022. https://cancercentrum.se/globalassests/om-rcc/sydost/pdf/nationell-kvalitetsregisterrapport-hudmelanom-1990-2022.pdf
Kappelin J, Green AC, Ingvar Å, Ahnlide I, Nielsen K. Incidence and trends of basal cell carcinoma in Sweden: a population-based registry study. Br J Dermatol 2022; 186: 963–969. DOI: https://doi.org/10.1111/bjd.20964
Vojvodic A, Vlaskovic-Jovicevic T, Vojvodic P, Vojvodic J, Goldust M, Peric-Hajzler Z, et al. Melanoma and mastocytosis. Open Access Maced J Med Sci 2019; 7: 3050–3052. DOI: https://doi.org/10.3889/oamjms.2019.772
Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26: 22–31. DOI: https://doi.org/10.1111/j.1468-3083.2012.04520.x
Stern RS. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 2012; 66: 553–562. DOI: https://doi.org/10.1016/j.jaad.2011.04.004
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Anna Bergström, Hans Hägglund, Anders Berglund, Gunnar Nilsson, Mats Lambe
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
